Everest Medicines Announces Up to HK$100 million Share Repurchase Program
SHANGHAI, Aug. 30, 2021 /PRNewswire/ — Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China…
